- Home
- AXTA vs IONS Comparison
AXTA vs IONS Comparison
Compare AXTA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXTA
- IONS
- Stock Information
- Founded
- AXTA 1910
- IONS 1989
- Country
- AXTA United States
- IONS United States
- Employees
- AXTA N/A
- IONS N/A
- Industry
- AXTA Paints/Coatings
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- AXTA Consumer Discretionary
- IONS Health Care
- Exchange
- AXTA Nasdaq
- IONS Nasdaq
- Market Cap
- AXTA 7.4B
- IONS 6.0B
- IPO Year
- AXTA 2014
- IONS 1991
- Fundamental
- Price
- AXTA $36.28
- IONS $31.43
- Analyst Decision
- AXTA Buy
- IONS Buy
- Analyst Count
- AXTA 12
- IONS 18
- Target Price
- AXTA $43.18
- IONS $62.00
- AVG Volume (30 Days)
- AXTA 1.9M
- IONS 1.5M
- Earning Date
- AXTA 02-04-2025
- IONS 02-19-2025
- Dividend Yield
- AXTA N/A
- IONS N/A
- EPS Growth
- AXTA 39.14
- IONS N/A
- EPS
- AXTA 1.49
- IONS N/A
- Revenue
- AXTA $5,262,100,000.00
- IONS $803,067,000.00
- Revenue This Year
- AXTA $3.74
- IONS N/A
- Revenue Next Year
- AXTA $2.25
- IONS $10.85
- P/E Ratio
- AXTA $24.36
- IONS N/A
- Revenue Growth
- AXTA 2.70
- IONS 30.57
- 52 Week Low
- AXTA $30.40
- IONS $31.41
- 52 Week High
- AXTA $41.66
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- AXTA 55.45
- IONS 33.19
- Support Level
- AXTA $33.40
- IONS $32.61
- Resistance Level
- AXTA $34.76
- IONS $35.37
- Average True Range (ATR)
- AXTA 0.60
- IONS 1.28
- MACD
- AXTA 0.38
- IONS -0.30
- Stochastic Oscillator
- AXTA 96.33
- IONS 0.36
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific and Latin America.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.